Research Papers:

HER3 and LINC00052 interplay promotes tumor growth in breast cancer

Ahmad Salameh, Xuejun Fan, Byung-Kwon Choi, Shu Zhang, Ningyan Zhang and Zhiqiang An _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:6526-6539. https://doi.org/10.18632/oncotarget.14313

Metrics: PDF 1945 views  |   HTML 2601 views  |   ?  


Ahmad Salameh1, Xuejun Fan1, Byung-Kwon Choi2, Shu Zhang3, Ningyan Zhang1, Zhiqiang An1

1Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA

2Department of Molecular and Human Genetics Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA

3Clinical Research Center, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

Correspondence to:

Ningyan Zhang, email: [email protected]

Zhiqiang An, email: [email protected]

Keywords: lncRNA, MCF7, T47D, HER3, NRG-1

Received: October 26, 2016     Accepted: December 13, 2016     Published: December 27, 2016


Here we report that the lncRNA LINC00052 expression correlates positively with HER3/ErbB3 levels in breast cancer cells. Gene silencing of LINC00052 diminished both LINC00052 and HER3 expression and reduced cancer cell growth in vitro and in vivo. LINC00052 overexpression promoted cancer cell growth in vitro and in vivo and increased HER3-mediated downstream signaling. Importantly, neutralization of HER3 signaling with HER3 targeting monoclonal antibodies blocked LINC00052 mediated cancer cell proliferation in vitro and tumor growth in vivo, suggesting LINC00052 promoting cancer growth through HER3 signaling. Taken together, our results indicate that high LINC00052 levels predict activation of HER3-mediated signaling, and LINC00052 expression level may serve as a potential biomarker for HER3 targeted antibody cancer therapies.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14313